Table 1 Patient characteristics and... | American Society of Hematology

Table 1

Patient characteristics and changes in BMD of the implanted bone and hIg levels in SCID-rab mice during the experiment

Patient no.	Stage*	Prior therapy	Isotype	MRI focal lesions, no.	MBS, no.†	DKK1 expression, signal‡	BMD, % change§		hIg, % change‖
Patient no.	Stage*	Prior therapy	Isotype	MRI focal lesions, no.	MBS, no.†	DKK1 expression, signal‡	IgG	DKK1 AB	IgG	DKK1 AB
1	II	No	IgGκ	1	0	1 392	93	107	144	94
2	IIIb	No	IgGλ	2	1	4 469	78	88	379	57
3	IIIb	No	IgGλ	100	100	9 755	99	102	129	89
4	II	No	IgGλ	2	0	1 448	104	99	1151	528
5	IIIa	No	IgGκ	12	7	12 948	98	145	243	153
6	III	No	IgGλ	0	0	4 896	102	114	119	75
7	IIIa	No	IgGκ	1	1	1 681	98	109	149	143
8	IIIa	No	IgGκ	21	11	16 152	68	83	284	181
9	IIIb	No	IgGλ	18	2	331	64	101	550	270
10	IIIb	Yes	IgGλ	26	13	1 361	98	110	180	228
11	III	No	IgGλ	9	0	257	78	102	1163	1155

Patient no.	Stage*	Prior therapy	Isotype	MRI focal lesions, no.	MBS, no.†	DKK1 expression, signal‡	BMD, % change§		hIg, % change‖
Patient no.	Stage*	Prior therapy	Isotype	MRI focal lesions, no.	MBS, no.†	DKK1 expression, signal‡	IgG	DKK1 AB	IgG	DKK1 AB
1	II	No	IgGκ	1	0	1 392	93	107	144	94
2	IIIb	No	IgGλ	2	1	4 469	78	88	379	57
3	IIIb	No	IgGλ	100	100	9 755	99	102	129	89
4	II	No	IgGλ	2	0	1 448	104	99	1151	528
5	IIIa	No	IgGκ	12	7	12 948	98	145	243	153
6	III	No	IgGλ	0	0	4 896	102	114	119	75
7	IIIa	No	IgGκ	1	1	1 681	98	109	149	143
8	IIIa	No	IgGκ	21	11	16 152	68	83	284	181
9	IIIb	No	IgGλ	18	2	331	64	101	550	270
10	IIIb	Yes	IgGλ	26	13	1 361	98	110	180	228
11	III	No	IgGλ	9	0	257	78	102	1163	1155

MRI indicates magnetic resonance imaging; MBS, metastatic bone survey; AB, antibody.

Stage at diagnosis, according to the Durie-Salmon staging system.

†

Metastatic bone survey, examined lytic lesions by standard x-rays.

‡

Signal intensity detected in CD138-selected myeloma plasma cells using microarray.^19,32,33 For comparison, median intensity level in normal plasma cells is 800.

Analyzed using PIXImus dual-energy x-ray absorptiometry (DEXA) and calculated as percent change from pretreatment level.

‖

Determined by ELISA and calculated as percent change from pretreatment level.

View Large

This Feature Is Available To Subscribers Only